Cancer World Magazine
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
NEWSLETTER  |  PRINT VERSION
Facebook
Twitter
LinkedIn
Cancer World Magazine
Cancer World Magazine
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
Cancer World Magazine > Partnership > EORTC > EORTC calls for the interests of patients to take centre stage in the development of new treatments

EORTC calls for the interests of patients to take centre stage in the development of new treatments

  • 21 February 2020
  • External Contributor
Total
0
Shares
0
0
0
0
0

With the arrival of precision medicine, the days of the old ‘one size fits all’ treatments seem long in the past. Precision oncology and new approaches to clinical research have meant a dramatic change in the field of cancer treatment. But precision medicine, promising as it is, brings its own challenge – how can we be sure that these targeted treatments are used optimally to the benefit of the individual patient?

New treatments now become available based on solid scientific rationale, thanks to our understanding of molecular biology and immunology. However, optimal use of new anti-cancer treatments remains poorly documented. Optimal patient population and cut-off values of biomarkers, treatment duration, sequence and combination are rarely informed, leaving patients, doctors and society facing many questions. In addition, all this is exacerbated by the often very high cost of new treatments. It is therefore essential to find an equilibrium between the interests and needs of all stakeholders, and define it around patientcentredness.

A newer version of the Clinical Trial Regulation will soon be implemented in Europe. However, it is not yet known whether it will address the issue of the qualification of studies designed to answer questions centred on patient care. On the contrary, it raises the risks that all Member States could adopt a position not necessarily based on medically informed criteria, and risks making therapeutic strategy trials yet more challenging to perform in the EU.

The current drug development paradigm has been criticised for being too drug-centred, and not focusing sufficiently on the patients who will eventually be consumers of the new therapies. A recent EORTC manifesto aims to try to find the balance between the interests and requirements of stakeholders (bit.ly/EORTC_ Treatment-Optimisation-Manifesto).

The EORTC consulted academic clinicians, representatives of patient organisations, regulatory and payer authorities, health technology assessments agencies, and industry. We now have much greater clarity on what is needed to put patients at the centre of the drug development process, and we were pleased to find that all stakeholders considered treatment optimisation tools to be valuable to address current gaps in evidence.

Treatment optimisation is a process intended to enhance the long term efficacy, adherence, safety, convenience and affordability of a therapy. Its ultimate goal is to expand access to effective treatment to all of those it will benefit. Currently, European patients and the healthcare system are penalised rather than aided by the regulatory hurdle. We need greater independence in assessing the role of treatments. Urgent reform is needed to assess interventional clinical research based on purpose and treatment modalities, not necessarily through the rigid application of inappropriate frameworks.

For more information visit: www.eortc.org

Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Avatar
External Contributor

You May Also Like
View Post
  • Articles
  • Delivery of Care

Immunotherapy toxicities demand a joined up approach from oncologists and organ specialists

  • Marc Beishon
  • 24 February 2021
View Post
  • News

Study brings mass biparametric MRI screening for prostate cancer a step closer

  • Janet Fricker
  • 23 February 2021
View Post
  • News

Oncology providers urged to offer healthy life style advice to breast cancer survivors

  • Janet Fricker
  • 19 February 2021
View Post
  • Articles
  • Policy

Beating cancer is complex – our messaging must be clear

  • Anna Wagstaff
  • 11 February 2021
View Post
  • News

Studies provide clarity on breast cancer genes for genetic panels

  • Janet Fricker
  • 9 February 2021
View Post
  • Supported contents

Moving towards efficiency in cancer care: Examples

  • Adriana Albini
  • 8 February 2021
View Post
  • News

EC publishes route map for tackling cancer

  • Janet Fricker
  • 5 February 2021
View Post
  • Profiles

World Cancer Day: we commemorate Professor Agim Sallaku

  • Alberto Costa
  • 3 February 2021
search
or search in Cancer World archive
Latest news
  • Study brings mass biparametric MRI screening for prostate cancer a step closer
    • 23 February 2021
  • Oncology providers urged to offer healthy life style advice to breast cancer survivors
    • 19 February 2021
  • Studies provide clarity on breast cancer genes for genetic panels
    • 9 February 2021
  • EC publishes route map for tackling cancer
    • 5 February 2021
  • Therapy targeting androgen receptors opens new chapter for hormone driven breast cancers
    • 27 January 2021
Latest printed issue
Article
  • Immunotherapy toxicities demand a joined up approach from oncologists and organ specialists
    • 24 February 2021
  • Beating cancer is complex – our messaging must be clear
    • 11 February 2021
  • Who wouldn’t want to cure 100% of childhood cancers?
    • 29 January 2021
Newsletter

Don't miss our newsletter

Would you like to receive our bimonthly e-newsletter with the latest news from Cancer World magazine?

Subscribe now
Social

Would you follow us ?

Contents
  • Moving towards efficiency in cancer care: Examples
    • 8 February 2021
  • World Cancer Day: we commemorate Professor Agim Sallaku
    • 3 February 2021
  • Gordon McVie 1945–2021: a lifetime dedicated to defeating cancer
    • 22 January 2021
MENU
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
Cancer World Magazine
  • About the Magazine
  • Articles
  • Media Corner
  • Privacy Policy
  • Cookie Policy

Cancer World is managed by SPCC Sharing Progress in Cancer Care | Piazza Indipendenza 2, 6500 Bellinzona - Switzerland | info@spcc.net

Archivio Cancerworld

Input your search keywords and press Enter.